ALK and neoplasm: As a proof of concept, the researchers used the knowledgebase to look at tumor sensitivity to ALK inhibitors — drugs that block common gene fusions involving ALK. They showed that the impact of resistance-conferring mutations depended on the nature of ALK’s fusion partner.